#### 

Authors: Cristina Soare, Karina Spiess, Alexandra Dumitrescu-Dragan, Mostafa Elgohary Vitreoretinal Service, Kingston and Richmond NHS Foundation Trust

### Background

#### Submacular haemorrhage (SMH):

Serious complication in neovascular age-related macular degeneration (nAMD) and retinal artery microaneurysm (RAM)

Associated with poor visual outcomes if untreated due to irreversible retinal damage from blood-induced iron toxicity.

#### Challenges and considerations:

Surgical methods can be effective but are invasive with significant risks.

Anti-VEGF therapy has shown visual improvement, though evidence is often limited and based on small studies.

#### Key factors influencing outcomes:

Duration, size, and thickness of SMH Initial visual acuity and retinal structure.

### Aim

To report clinical characteristics, management and outcomes of SMH

## Patients and methods

**Design:** retrospective interventional series of 90 eyes (90 patients) between July 2014 - August 2023

#### **Definitive intervention:**

- IVT tPA + PD ± anti-VEGF n=62
- IVT tPA ± anti-VEGF n=10
- IVT tPA ± anti-VEGF followed by surgical drainage n=12
- IVT tPA + PD ± anti-VEGF followed by surgical drainage n=6

IVT tPA dose was 50-200mg and was repeated in 16 eyes.

PD: 67 eyes 0.5 mL C3F8 100%, 1 eye 0.5 mL SF6 100%

No posture

#### Results

Mean age 83 ±9 years

**Female:Male =** 1.4:1

#### Aetiology:

- Wet AMD (including IPCV): 75 eyes (83.3%)
  - 55% treatment naïve
  - 45% previously treated
- RAM: 14 eyes (15.5%)
- Sorsby's macular degeneration: 1 eye (1.1%)

**Median length of symptoms:** 4 days (IQR 1-7)

Median follow-up: 108 weeks (IQR 55-185)

Anticoagulants/antiplatelets: 31/90 (34.4%) patients



#### Size of SMH

16/90 eyes had rebleed following the initial treatment.

#### Results



# **Kingston and Richmond NHS Foundation Trust**

### Results

outcomes in clinical practice.